EXEL Stock Summary and Trading Ideas (Exelixis | NASDAQ:EXEL)

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis trades on the NASDAQ stock market under the symbol EXEL.

As of April 10, 2026, EXEL stock price declined to $44.27 with 2,771,224 million shares trading.

EXEL has a beta of 1.80, meaning it tends to be more sensitive to market movements. EXEL has a correlation of 0.37 to the broad based SPY ETF.

EXEL has a market cap of $11.50 billion. This is considered a Large Cap stock.

Last quarter Exelixis reported $599 million in Revenue and $.94 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.18.

In the last 3 years, EXEL traded as high as $49.62 and as low as $18.08.

The top ETF exchange traded funds that EXEL belongs to (by Net Assets): IJH, VTI, VB, VBK, VXF.

EXEL has underperformed the market in the last year with a price return of +28.5% while the SPY ETF gained +30.9%. However, in the short term, EXEL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +0.5% vs -1.8% return in SPY. But in the last 2 weeks, EXEL shares have been beat by the market, returning +6.6% compared to an SPY return of +7.2%.

EXEL support price is $44.66 and resistance is $46.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EXEL shares will trade within this expected range on the day.